anyone know the purpose of filing the amended annual report, along with the statement that the info was going to be filed as part of the proxy? Yet no proxy was filed yet, but surely one will be, so why not just include the info with the proxy?
Maybe a timing thing, where the amendment was due but the proxy was not ready?
Interesting quote from that link...Intellia you don't hear much about these days but just having Intellia with PS Targeting patent holder Troy Luster makes them one to keep an eye on, especially if any undisclosed collaborations with Peregrine going on ...
"We believe Juno and Bluebird, the two leading independent CAR-T developers, are obvious (acquisition) plays following Kite's takeout," he said. Other earlier-stage potential targets include Intellia (NTLA), Fate Therapeutics (FATE) and Tesaro (TSRO)."
PATENTS: ‘BETABODIES’ patent app #20060228299, filed 1-24-2006, pub 10-12-2006 "Constructs Binding to Phosphatidylserine and Their Use in Disease Treatment" ("Betabodies & Receptorbodies”) Inventors: Philip E. Thorpe, Troy A. Luster, Steven W. King Assignee1: BOARD OF REGENTS, UNIV. OF TEXAS SYSTEM, 201 W. 7TH ST, AUSTIN, TX Assignee2: PEREGRINE PHARMACEUTICALS, INC., 14272 FRANKLIN AVE, TUSTIN, CA USPTO: http://tinyurl.com/649986 http://investorshub.advfn.com/boards/read_msg.aspx?message_id=89680206
April 3, 2013 Phil was a terrific scientist and an excellent mentor to myself and countless others. I'll always look back fondly at my time working in his lab at UT Southwestern. He will be missed but his contributions to science live on forever. Troy Luster, Boston http://investorshub.advfn.com/boards/read_msg.aspx?message_id=88643562
News 
Market Data 
Discover 
